Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biolinerx Ltd ADR (BLRX)

Biolinerx Ltd ADR (BLRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Biolinerx Ltd ADR 2 HAMA-AYAN STREET MODI-IN TECHNOLOGY PARK MODI-IN L3 7177871 ISR

www.biolinerx.com P: 972-2548-9100 F: 972-864-2910

Description:

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

Key Statistics

Overview:

Market Capitalization, $K 54,766
Enterprise Value, $K 60,286
Shares Outstanding, K 79,939
Annual Sales, $ 4,800 K
Annual Net Income, $ -60,610 K
Last Quarter Sales, $ 4,800 K
Last Quarter Net Income, $ -13,880 K
EBIT, $ -44,110 K
EBITDA, $ -42,730 K
60-Month Beta 1.50
% of Insider Shareholders 1.10%
% of Institutional Shareholders 1.56%
Float, K 79,060
% Float 98.90%
Short Volume Ratio 0.44

Growth:

1-Year Return -56.54%
3-Year Return -75.96%
5-Year Return -87.43%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 70.16%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 03/26/24
Latest Earnings Date 05/22/24
Earnings Per Share ttm -0.90
EPS Growth vs. Prev Qtr 50.00%
EPS Growth vs. Prev Year -66.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-15 on 07/15/19

BLRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -280.21%
Return-on-Assets % -99.22%
Profit Margin % -1,262.71%
Debt/Equity 0.74
Price/Sales 10.99
Price/Cash Flow N/A
Price/Book 3.74
Book Value/Share 0.18
Interest Coverage -26.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar